Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 215 vs bevacizumab in advanced non-squamous NSCLC (China consistency study)
CTR20200442Phase 3Terminated
- Sponsor
- Amgen
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab-bvzr in non-small cell lung cancer (NSCLC), sponsored by Amgen. Started Apr 2020; status: terminated.
02
Drugs
bevacizumab-bvzr
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200442.